CL vs PG

Key Takeaways

• Colgate-Palmolive (CL) holds a commanding ~41% global toothpaste market share and has delivered consistent organic sales growth, supported by its focused oral care dominance and expanding pet nutrition segment.
• Procter & Gamble (PG) is the far larger entity with a $345+ billion market capitalization and a diversified portfolio spanning ten product categories, generating over $84 billion in annual net sales.
• Both companies face persistent tariff-related headwinds and cautious consumer spending patterns, though PG's exposure is significantly larger — management has cited roughly $400 million in annual after-tax tariff costs.
• CL has demonstrated stronger recent organic sales momentum, while PG's volumes have been flat to declining in several key categories, including Baby, Feminine & Family Care.
• PG offers a higher dividend yield (approximately 2.9%) and a longer dividend growth streak at 69 consecutive years, compared to CL's 63-year streak and yield near 2.4%.
• Both companies are executing multi-year restructuring programs aimed at cost savings and operational efficiency, signaling a disciplined approach to margin protection.

Introduction

Within the consumer staples universe, few comparisons carry as much weight as CL versus PG. Colgate-Palmolive and Procter & Gamble are two of the most iconic names in household and personal care, each with a multi-generational track record of dividend growth, global brand recognition, and defensive characteristics that appeal to income-oriented and risk-averse investors alike. Yet beneath the surface, these two companies represent fundamentally different approaches to the consumer goods market — one a focused category leader, the other a diversified behemoth. This comparison examines how both stocks are positioned in the current market environment and what the divergence in their recent performance signals for traders and long-term investors.

CL Overview and Recent Performance

Colgate-Palmolive operates from a position of extraordinary category dominance, holding an estimated 41.3% share of the global toothpaste market and 32.4% of the manual toothbrush market as of its most recent reporting periods. The company's portfolio spans Oral Care, Personal Care, Home Care, and Pet Nutrition — the latter driven by its Hill's Science Diet and Hill's Prescription Diet brands. In its full-year 2025 results, CL reported net sales of $20.38 billion, representing a 1.4% increase year over year, while organic sales grew by the same magnitude. Base Business earnings per share (EPS) — a non-GAAP (Generally Accepted Accounting Principles) metric that excludes certain one-time items — rose 3% to $3.69. The company generated a record $4.2 billion in net cash from operations and returned $2.9 billion to shareholders through dividends and share repurchases.

Recent weeks have seen CL's management articulate an ambitious 2030 strategy centered on science-based innovation, AI-driven analytics, and omni-channel demand generation. The company is also executing a three-year Strategic Growth and Productivity Program expected to generate between $200 million and $300 million in cumulative pre-tax savings through 2028. However, CL's fourth-quarter 2025 results carried a notable blemish: a $919 million non-cash goodwill and intangible assets impairment charge tied to the Filorga skin health business, reflecting weaker-than-expected performance in China. On a Base Business basis, CL's underlying operational trends remain steady, with pricing power contributing positively to organic growth even as volume growth has been mixed across regions.

PG Overview and Recent Performance

Procter & Gamble is the larger and more diversified of the two companies, with a market capitalization exceeding $345 billion and annual revenues of approximately $84.3 billion in its fiscal year 2025, which ended in June 2025. PG operates across five major segments — Beauty, Grooming, Health Care, Fabric & Home Care, and Baby, Feminine & Family Care — anchored by globally recognized brands including Tide, Pampers, Gillette, Olay, and Crest. The company's scale, retail relationships, and advertising budget provide competitive advantages that are difficult for smaller rivals to replicate.

In recent quarters, PG's performance has reflected the challenging consumer environment. During its most recently reported quarter (Q4 CY2025, ending December 2025), organic sales were flat year over year, with 1% pricing gains offset by a 1% decline in volumes. Beauty and Health Care segments led with 5% organic growth each, while Baby, Feminine & Family Care declined 4%. Management has pointed to heightened promotional intensity in North America and Europe, cautious consumer behavior, and tough prior-year comparisons as near-term headwinds. PG is also navigating a substantial restructuring effort — targeting up to 7,000 non-manufacturing role reductions and up to $1.5 billion in cost-of-goods-sold savings through its "Supply Chain 3.0" initiative — while absorbing approximately $400 million in annual after-tax tariff costs. The company's 69-year streak of consecutive dividend increases, the longest among major consumer staples names, remains a defining feature for income-focused shareholders.

Trending AI Robots

For traders seeking an analytical edge in comparing stocks like CL and PG, Tickeron's Trending AI Robots page offers a curated selection of AI-powered trading bots tailored to current market conditions. Tickeron hosts hundreds of AI trading bots that collectively trade thousands of different tickers, but only those demonstrating the strongest adaptability and performance metrics earn placement in this curated section. The bots vary widely in their trading styles — ranging from short-term swing trading to longer-duration trend-following — and each comes with its own track record, risk profile, and basket of targeted tickers. Some bots in the Trending section have shown annualized returns that meaningfully outperform their benchmark indices, though past performance is not indicative of future results. Exploring the Trending AI Robots page can help traders identify which automated strategies are currently aligned with the market's evolving dynamics.

Head-to-Head Comparison

When placed side by side, several structural contrasts emerge between CL and PG. The most obvious is scale: PG generates roughly four times the annual revenue of CL and carries a market capitalization nearly five times larger. This scale grants PG advantages in retail shelf presence, advertising leverage, and supply chain bargaining power, but it also means the company must defend market share across a broader, more complex portfolio — and tariff exposure is materially larger in absolute dollar terms.

CL's more focused business model is both its greatest strength and its most notable limitation. Dominance in oral care — a category with relatively stable demand and high brand loyalty — provides a durable earnings stream, while Hill's Pet Nutrition adds a differentiated growth vector. However, CL remains more concentrated by category, and missteps in core segments (such as the Filorga skin health impairment) can carry disproportionate weight in reported results.

From a dividend perspective, PG's 69-year increase streak and higher yield give it an edge for pure income investors. CL's 63-year streak is also impressive, but the lower yield and smaller free cash flow base make PG the more compelling income generator in absolute terms. On valuation, PG trades at a forward price-to-earnings (P/E) ratio of roughly 21–22x, modestly below its five-year median, while CL trades at approximately 24x — a premium that reflects the market's confidence in its sharper near-term growth trajectory. Notably, CL shares have outperformed PG shares in recent months, and analyst EPS estimate revisions have trended more favorably for CL, suggesting stronger near-term earnings momentum.

Both companies face shared macro risks: tariff uncertainty, foreign exchange volatility, cautious consumer spending patterns, and rising competitive intensity from private-label alternatives. PG's restructuring is more extensive and potentially transformative, but it also introduces execution risk over the next 12 to 24 months. CL's productivity program is smaller in scale but may offer a faster path to margin stabilization.

Tickeron AI Verdict

Based on observable trends — including organic sales momentum, estimate revision direction, relative price performance, and the magnitude of tariff and restructuring headwinds — Tickeron's AI analytical framework would likely tilt toward CL in the current environment. Colgate-Palmolive's cleaner near-term growth narrative, focused category leadership, and comparatively more contained restructuring disruption create a profile that trend-following models tend to favor. That said, PG remains a fundamentally stronger income vehicle with unmatched dividend durability, and its discounted valuation relative to historical averages could attract value-oriented and mean-reversion strategies. The AI verdict is probabilistic rather than absolute: CL appears better positioned in the near term, while PG's long-term compounding credentials remain intact for patient investors.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations